RegeneRx Biopharmaceuticals’ (RGRX) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of RegeneRx Biopharmaceuticals Inc (NASDAQ:RGRX) in a research report report published on Thursday morning. The firm currently has a $2.00 target price on the stock.
Shares of RegeneRx Biopharmaceuticals (NASDAQ:RGRX) remained flat at $0.37 on Thursday. The company had a trading volume of 16,200 shares. The company has a 50-day moving average of $0.38 and a 200 day moving average of $0.48. RegeneRx Biopharmaceuticals has a 12 month low of $0.28 and a 12 month high of $0.75. The company’s market cap is $39.51 million.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Stock Ratings for RegeneRx Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.